Apremilast is effective for the treatment of moderate-to-severe plaque psoriasis short-term in pediatric patients.

Plaque psoriasis patients with lower blood monocyte counts at baseline achieved early response when treated with secukinumab.

Guselkumab has shown improvements in skin clearance, scalp itch, and patient-report health-related QoL in skin of colour patients.

IL-23 inhibitors used to treat psoriasis patients are associated with the lowest risk of paradoxical AD compared to other biologics.

A lack of published psoriasis images complicates communication with patients, according to a study from the University of Gothenburg,...

Psoriasis patients with pruritis and related sleep distrubances showed a lower quality of life in all domains.

Researchers developed a PRESTO tool using clinical variables to predict PsA risk in PsO patients with reasonable accuracy.

Roflumilast showed significant improvement in disease severity in 95% of plaque psoriasis patients by week 8.